The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final skin toxicity (ST) and patient-reported outcomes (PRO) results from PRIME: A randomized phase III study of panitumumab (pmab) plus FOLFOX4 (CT) for first-line metastatic colorectal cancer (mCRC).
Jean Yves Douillard
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Salvatore Siena
Consultant or Advisory Role - Amgen; AstraZeneca; Merck Serono; Roche
Josep Tabernero
Consultant or Advisory Role - Amgen; Merck Serono; Roche
Ronald L. Burkes
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Mario Edmundo Barugel
Consultant or Advisory Role - Amgen; Roche
Honoraria - Roche
Yves Humblet
Honoraria - Amgen
Research Funding - Amgen
David Cunningham
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
Feng Xu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Zhongyun Zhao
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Roger Sidhu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen